Pesquisar
Tempest Therapeutics Inc
TPSTAdicionar à lista de desejos
1.030USD
+0.275+36.42%
Horário de mercado 09/16, 11:20（ET）
16.46MValor de mercado
0.03P/L TTM
Mais detalhes de Tempest Therapeutics Inc Empresa
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Tempest Therapeutics Inc Perfil
Código da empresaTPST
Nome da EmpresaTempest Therapeutics Inc
Data de listagemOct 04, 2012
CEO- -
Número de funcionários24
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 04
Endereço2000 Sierra Point Parkway
CidadeBRISBANE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94005
Telefone14157988589
Sitehttps://www.tempesttx.com/
Código da empresaTPST
Data de listagemOct 04, 2012
CEO- -
Executivos da empresa Tempest Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
666.00
--
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
590.00
--
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Dr. Ronit Simantov, M.D.
Dr. Ronit Simantov, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Trojanowski
Mr. Justin Trojanowski
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance, Corporate Controller, Treasurer, Corporate Secretary
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance, Corporate Controller, Treasurer, Corporate Secretary
--
--
Mr. John David Yee, M.D.
Mr. John David Yee, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
666.00
--
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
590.00
--
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
Perguntas frequentes
Quem são os cinco principais acionistas de Tempest Therapeutics Inc?
Os cinco principais acionistas de Tempest Therapeutics Inc são: Dr. Matthew (Matt) Angel, Ph.D.
Quantas instituições possuem ações da Tempest Therapeutics Inc (TPST)?
Em 2026Q1, 68 instituições possuíam ações da Tempest Therapeutics Inc, com valor de mercado aproximado de 4.51M, representando 31.43% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 3582210.00.